Medical complications in long-term survivors with X-linked myotubular myopathy - PubMed (original) (raw)
Medical complications in long-term survivors with X-linked myotubular myopathy
G E Herman et al. J Pediatr. 1999 Feb.
Abstract
Objectives: X-linked myotubular myopathy (MTM1) is a rare developmental disorder of skeletal muscle characterized by the presence of central nuclei in biopsy specimens from affected male subjects. Until recently, the disorder was usually fatal within the first year of life. This study was undertaken to determine the outcome in long-term survivors (>1 year of age) with MTM1.
Methods: Clinical data were obtained on 55 male subjects from 49 independent North American families for which a mutation was identified in the X-linked myotubularin gene by direct genomic sequencing. Medical records were reviewed and families were interviewed to ascertain features at birth, length of survival, developmental milestones, and medical complications.
Results: Seventy-four percent (26 of 35) of the affected male subjects over the age of 1 year are living (range, 1 to 27 years); 80% remain completely or partially ventilator-dependent. In the absence of significant hypoxia, cognitive development is normal, and the muscle disorder appears nonprogressive. Several patients have had other medical problems not previously reported to be associated with MTM1. These include pyloric stenosis (4 male subjects from 3 families), spherocytosis (2 patients), gallstones (4 patients), kidney stones or nephrocalcinosis (2 patients), a vitamin K responsive bleeding diathesis (2 patients), and height >/=90% for age (40% of the patients). Six patients have had biochemical evidence of liver dysfunction, and 2 patients died after significant liver hemorrhage.
Conclusions: These data suggest that the prognosis for X-linked MTM may not be as poor as previously reported. However, at least some long-term survivors appear at risk for medical complications involving other organ systems, and patients should be carefully monitored for these potentially life-threatening complications. The pleiotropic symptoms demonstrated in these patients strongly suggest that the function of the MTM1 protein is not limited to developing muscle cells.
Similar articles
- [X-linked recessive myotubular myopathy with a splice-site mutation in the myotubularin gene].
Watanabe T, Watanabe M, Saito T, Higashitani A, Tanaka S, Nishino I, Nonaka I. Watanabe T, et al. No To Hattatsu. 1998 Nov;30(6):523-7. No To Hattatsu. 1998. PMID: 9844418 Review. Japanese. - Characterization of 34 novel and six known MTM1 gene mutations in 47 unrelated X-linked myotubular myopathy patients.
Tanner SM, Schneider V, Thomas NS, Clarke A, Lazarou L, Liechti-Gallati S. Tanner SM, et al. Neuromuscul Disord. 1999 Jan;9(1):41-9. doi: 10.1016/s0960-8966(98)00090-x. Neuromuscul Disord. 1999. PMID: 10063835 - Characterization of mutations in fifty North American patients with X-linked myotubular myopathy.
Herman GE, Kopacz K, Zhao W, Mills PL, Metzenberg A, Das S. Herman GE, et al. Hum Mutat. 2002 Feb;19(2):114-21. doi: 10.1002/humu.10033. Hum Mutat. 2002. PMID: 11793470 - MTM1 gene mutations in Japanese patients with the severe infantile form of myotubular myopathy.
Nishino I, Minami N, Kobayashi O, Ikezawa M, Goto Y, Arahata K, Nonaka I. Nishino I, et al. Neuromuscul Disord. 1998 Oct;8(7):453-8. doi: 10.1016/s0960-8966(98)00075-3. Neuromuscul Disord. 1998. PMID: 9829274 - [Myotubular myopathy. Case report and review of the literature].
Kovács SK, Korcsik J, Szabó H, Bódi I, Katona M, Bereg E, Endreffy E, Túri S, Hortobágyi T, Sztriha L. Kovács SK, et al. Orv Hetil. 2007 Sep 16;148(37):1757-62. doi: 10.1556/OH.2007.28054. Orv Hetil. 2007. PMID: 17827085 Review. Hungarian.
Cited by
- Two Cases of X-Linked Myotubular Myopathy with Novel MTM1 Mutations.
Lee EH, Yum MS, Park SJ, Lee BH, Kim GH, Yoo HW, Ko TS. Lee EH, et al. J Clin Neurol. 2013 Jan;9(1):57-60. doi: 10.3988/jcn.2013.9.1.57. Epub 2013 Jan 3. J Clin Neurol. 2013. PMID: 23346162 Free PMC article. - Adult _MTM1_-related myopathy carriers: Classification based on deep phenotyping.
Cocanougher BT, Flynn L, Yun P, Jain M, Waite M, Vasavada R, Wittenbach JD, de Chastonay S, Chhibber S, Innes AM, MacLaren L, Mozaffar T, Arai AE, Donkervoort S, Bönnemann CG, Foley AR. Cocanougher BT, et al. Neurology. 2019 Oct 15;93(16):e1535-e1542. doi: 10.1212/WNL.0000000000008316. Epub 2019 Sep 20. Neurology. 2019. PMID: 31541013 Free PMC article. - European Neuromuscular Centre consensus statement on anaesthesia in patients with neuromuscular disorders.
van den Bersselaar LR, Heytens L, Silva HCA, Reimann J, Tasca G, Díaz-Cambronero Ó, Løkken N, Hellblom A, Hopkins PM, Rueffert H, Bastian B, Vilchez JJ, Gillies R, Johannsen S, Veyckemans F, Muenster T, Klein A, Litman R, Jungbluth H, Riazi S, Voermans NC, Snoeck MMJ. van den Bersselaar LR, et al. Eur J Neurol. 2022 Dec;29(12):3486-3507. doi: 10.1111/ene.15526. Epub 2022 Sep 14. Eur J Neurol. 2022. PMID: 35971866 Free PMC article. - Myotubularin controls desmin intermediate filament architecture and mitochondrial dynamics in human and mouse skeletal muscle.
Hnia K, Tronchère H, Tomczak KK, Amoasii L, Schultz P, Beggs AH, Payrastre B, Mandel JL, Laporte J. Hnia K, et al. J Clin Invest. 2011 Jan;121(1):70-85. doi: 10.1172/JCI44021. Epub 2010 Dec 6. J Clin Invest. 2011. PMID: 21135508 Free PMC article. - Real-world analysis of healthcare resource utilization by patients with X-linked myotubular myopathy (XLMTM) in the United States.
Graham RJ, Darras BT, Haselkorn T, Fisher D, Genetti CA, Miller W, Beggs AH. Graham RJ, et al. Orphanet J Rare Dis. 2023 Jun 6;18(1):138. doi: 10.1186/s13023-023-02733-2. Orphanet J Rare Dis. 2023. PMID: 37280644 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical